Tvardi Therapeutics Inc.
Clinical-stage biopharma developing oral STAT3 inhibitors for fibrotic diseases.
TVRD | IL
Overview
Corporate Details
- ISIN(s):
- US1407553072
- LEI:
- 549300COVOY41P0GZ881
- Country:
- United States of America
- Address:
- 3 Sugar Creek Ctr Blvd, Ste 525, TX 77478 Sugar Land
- Website:
- https://tvarditherapeutics.com/
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies. The company's platform targets STAT3 (Signal Transducer and Activator of Transcription 3), a key regulatory protein implicated in the progression of various diseases. Tvardi's primary focus is on treating fibrosis-driven diseases with significant unmet medical need. Its pipeline includes candidates in Phase 2 clinical trials for indications such as idiopathic pulmonary fibrosis. In 2025, the company completed a merger with Cara Therapeutics.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Tvardi Therapeutics Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Tvardi Therapeutics Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
